Pulmonology

ASCO Journal Club

Journal Club Q&A done in partnership with ASCO the Journal of Clinical Oncology

Questions discussed in this category

How are you using liquid biopsy in the routine management of your patients with metastatic NSCLC?

Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?

2 Answers available

Papers discussed in this category

JCO Precision Oncology, 2017 Sep 29

Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician

Sci Rep, 2014 Sep 09

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.

Medicine (Baltimore),

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-01

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Related Topics in Pulmonology